These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 17973895

  • 1. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
    Panzer S.
    Vox Sang; 2008 Jan; 94(1):1-5. PubMed ID: 17973895
    [Abstract] [Full Text] [Related]

  • 2. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD, Herrington JD.
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [Abstract] [Full Text] [Related]

  • 3. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
    Kurata Y.
    Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
    [No Abstract] [Full Text] [Related]

  • 4. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
    Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S.
    Thromb Haemost; 2008 Jan; 99(1):4-13. PubMed ID: 18217129
    [Abstract] [Full Text] [Related]

  • 5. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A.
    Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
    [Abstract] [Full Text] [Related]

  • 6. New options after first-line therapy for chronic immune thrombocytopenic purpura.
    Burzynski J.
    Am J Health Syst Pharm; 2009 Jan 15; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
    [Abstract] [Full Text] [Related]

  • 7. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb 09; 51(1305):10-1. PubMed ID: 19197233
    [Abstract] [Full Text] [Related]

  • 8. Positioning new treatments in the management of immune thrombocytopenia.
    Arnold DM.
    Pediatr Blood Cancer; 2013 Feb 09; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
    [Abstract] [Full Text] [Related]

  • 9. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses.
    Arnold DM, Nazi I, Kelton JG.
    Expert Opin Investig Drugs; 2009 Jun 09; 18(6):805-19. PubMed ID: 19426124
    [Abstract] [Full Text] [Related]

  • 10. [New treatment options for primary immune thrombocytopenia].
    Gudbrandsdottir S, Frederiksen H, Birgens HS, Nielsen CH, Nielsen OJ, Stentoft J, Hasselbalch HC.
    Ugeskr Laeger; 2011 Jan 24; 173(4):271-4. PubMed ID: 21262171
    [Abstract] [Full Text] [Related]

  • 11. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
    Boyers D, Jia X, Crowther M, Jenkinson D, Fraser C, Mowatt G.
    Health Technol Assess; 2011 May 24; 15 Suppl 1():23-32. PubMed ID: 21609650
    [Abstract] [Full Text] [Related]

  • 12. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
    Puavilai T, Thadanipon K, Rattanasiri S, Ingsathit A, McEvoy M, Attia J, Thakkinstian A.
    Br J Haematol; 2020 Feb 24; 188(3):450-459. PubMed ID: 31423574
    [Abstract] [Full Text] [Related]

  • 13. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ.
    Eur J Haematol Suppl; 2008 Feb 24; (69):9-18. PubMed ID: 18211568
    [Abstract] [Full Text] [Related]

  • 14. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT, Viallard JF, Nurden P.
    Lancet; 2009 May 02; 373(9674):1562-9. PubMed ID: 19324405
    [Abstract] [Full Text] [Related]

  • 15. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    Godeau B, Centre de référence labellisé pour la prise en charge des cytopénies auto-immunes de l'adulte.
    Rev Med Interne; 2009 Mar 02; 30(3):203-5. PubMed ID: 19019500
    [No Abstract] [Full Text] [Related]

  • 16. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M.
    Lancet; 2009 Feb 21; 373(9664):641-8. PubMed ID: 19231632
    [Abstract] [Full Text] [Related]

  • 17. Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
    Tamary H, Roganovic J, Chitlur M, Nugent DJ.
    Ann Hematol; 2010 Jul 21; 89 Suppl 1(Suppl 1):5-10. PubMed ID: 20358200
    [Abstract] [Full Text] [Related]

  • 18. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.
    Altomare I, Wasser J, Pullarkat V.
    Am J Hematol; 2012 Oct 21; 87(10):984-7. PubMed ID: 22729832
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
    Yang R, Lin L, Yao H, Ji O, Shen Q.
    Hematology; 2019 Dec 21; 24(1):290-299. PubMed ID: 30661482
    [Abstract] [Full Text] [Related]

  • 20. New insights and therapeutics for immune-mediated thrombocytopenia.
    Metjian A, Abrams CS.
    Expert Rev Cardiovasc Ther; 2008 Jan 21; 6(1):71-84. PubMed ID: 18095908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.